hcb101
mAbexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 2, 2023 (NCT05892718)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Leukocyte surface antigen CD47INHIBITOR
CD47 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07136545 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2025 | Chang Gung University, FBD Biologics, National Taiwan University, Taipei Veteran General hospital |
| NCT07204574 | Phase 1/Phase 2 (Phase 2) | May 14, 2025 | Chang Gung University, FBD Biologics |
| NCT06771622 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2025 | FBD Biologics |
| NCT05892718 | Phase 1 | Oct 2, 2023 | FBD Biologics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| FBD Biologics | For profit | 4 | 2 | 2 | 2023 |
| Chang Gung University | Academic/Hospital | 2 | 1 | 1 | 2025 |
| National Taiwan University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Taipei Veteran General hospital | Government | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1